Our Mission
PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- CAR-T Upfront for High-risk Myeloma?
CAR-T Upfront for High-risk Myeloma?
According to the research below, CAR-T therapy used upfront for high-risk myeloma patients works well. As always however, the devil is in the details.
If you are diagnosed with high-risk MM your therapy plan options are limited. I say limited because high-risk MM patients usually relapse sooner than other MM patients.
The question then, is if the high-risk MM patient will, on average, enjoy a longer overall survival than he/she would undergoing conventional chemo combinations.
Explanation of the KarMMa-4 CAR-T upfront for high-risk MM patients-
The good news for MMers interested in the KarMMa-4 trial is that
- 100% of patients responded to therapy and
- side effects appears to be minimal
The bad news is that the efficacy or long-term survival of MMers is not known. One patient relapsed at 3 months and other patients relapsed but it is too soon to determine the overall duration of response.
As a long-term survivor of MM myself, I believe adverse events or side effects, especially long-term side effects are often underestimated in clinical trials and therefore, an an unknown that must be known.
If you’d like to learn more about high-risk multiple myeloma email me at David.PeopleBeatingCancer@gmail.com
Good luck,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma
“Question What are the safety, pharmacokinetic, and survival outcomes of B-cell maturation antigen (BCMA)/CD19 dual-targeting chimeric antigen receptor (CAR) T-cell therapy in individuals with high-risk newly diagnosed multiple myeloma who receive it as a frontline treatment?
Findings In this single-arm, open-label phase 1 cohort study including 19 patients in the efficacy analysis, all patients (100%) achieved stringent complete responses and minimal residual disease negativity. The treatment showed a favorable safety profile in the 22 patients in the safety analysis, with 6 patients (27%) experiencing mild to moderate cytokine release syndrome and no patients with immune effector cell–associated neurotoxicity syndrome.
Meaning These results suggest that the BCMA/CD19 dual-targeting CAR T-cell therapy, GC012F, is a safe treatment associated with positive health and survival outcomes for patients with high-risk newly diagnosed multiple myeloma eligible for transplant following initial induction therapy…
Intervention Patients underwent 2 cycles of induction therapy, followed by GC012F infusion (at 1 × 105 cells/kg, 2 × 105 cells/kg, or 3 × 105 cells/kg)…
Patients achieving minimal residual disease (MRD) negativity8 with complete response (CR) could be maintained on lenalidomide from month 6 based on investigators’ discretion (eAppendix in Supplement 1).
The primary end points included:
- adverse events (AEs)9;
- overall response rate (ORR)10;
- CR and stringent CR (sCR) rates;
- MRD-negative rate;
- duration of response (DOR);
- and progression-free survival (PFS).
Secondary end points included overall survival (OS); time to first response; time to best response; and pharmacokinetic and biomarkers.
Conclusions and Relevance The findings of this single-arm, open-label phase 1 cohort study suggest that GC012F may be a safe treatment associated with positive health and survival outcomes for patients with high-risk NDMM eligible for transplant. Owing to the small sample size, further studies with larger cohorts and longer follow-up durations are needed…